噻嗪类利尿剂与常染色体显性多囊肾病疾病进展速率:一项观察性研究
本研究基于533例ADPKD患者的观察性队列,分析噻嗪类利尿剂使用与eGFR下降及复合肾脏终点的关联。结果显示,噻嗪类使用与eGFR下降速率无关,粗模型下复合终点风险升高但校正后无显著关联,提示噻嗪类对ADPKD疾病进展无不利影响,可作为二线降压药。
要点
- 噻嗪类使用与ADPKD患者eGFR下降速率无显著差异。
- 粗模型下复合肾脏终点风险升高,但校正年龄性别后无显著关联。
- 噻嗪类未显示对ADPKD疾病进展不利,可作二线降压药。
核心结论
- 噻嗪类利尿剂对ADPKD疾病进展速率无不利影响,可作为二线降压药。
研究设计与样本
- 观察性队列研究,纳入533例ADPKD患者,随访3.9年(四分位距2.5-4.9)。
- 使用线性混合模型评估eGFR下降,Cox比例风险模型评估复合肾脏终点。
主要发现
- 噻嗪类使用者eGFR下降速率差异为-0.35 mL/min/1.73 m2/年(95%CI -0.83至-0.14),P=0.2。
- 校正混杂因素后eGFR下降差异为0.08 mL/min/1.73 m2/年(95%CI -0.46至-0.62),P=0.8。
- 粗模型复合肾脏终点HR 1.53(95%CI 1.05-2.23),P=0.03;最终模型HR 0.80(95%CI 0.50-1.29),P=0.4。
- 噻嗪类使用者血浆和肽素更高,但校正年龄性别后差异消失;肾素和醛固酮更高。
临床怎么用
- ADPKD患者可在RAAS阻断基础上使用噻嗪类作为二线降压药。
- 使用噻嗪类时无需过度担忧疾病进展加速。
局限性
- 观察性设计可能存在残余混杂。
- 样本量有限,随访时间较短。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In autosomal dominant polycystic kidney disease (ADPKD), hypertension is prevalent and cardiovascular events are the main cause of death. Thiazide diuretics are often prescribed as second-line antihypertensives, on top of renin-angiotensin-aldosterone system (RAAS) blockade. There is a concern, however, that diuretics may increase vasopressin concentration and RAAS activity, thereby worsening disease progression in ADPKD. We aimed to investigate the validity of these suggestions. METHODS: We analysed an observational cohort of 533 ADPKD patients. Plasma copeptin (surrogate for vasopressin), aldosterone and renin were measured by enzyme-linked immunosorbent assay and radioimmunoassay, respectively. Linear mixed models were used to assess the association of thiazide use with estimated glomerular filtration rate (eGFR) decline and Cox proportional hazards models for the association with the composite kidney endpoint of incident end-stage kidney disease, 40% eGFR decline or death. RESULTS: A total of 23% of participants (n = 125) used thiazide diuretics at baseline. Compared with non-users, thiazide users were older, a larger proportion was male, they had lower eGFRs and similar blood pressure under more antihypertensives. Plasma copeptin was higher, but this difference disappeared after adjustment for age and sex. Both renin and aldosterone were higher in thiazide users. There was no difference between thiazide users and non-users in the rate of eGFR decline {difference -0.35 mL/min/1.73 m2 per year [95% confidence interval (CI) -0.83 to -0.14], P = 0.2} during 3.9 years of follow-up (interquartile range 2.5-4.9). This did not change after adjustment for potential confounders [difference final model: 0.08 mL/min/1.73 m2 per year [95% CI -0.46 to -0.62], P = 0.8). In the crude model, thiazide use was associated with a higher incidence of the composite kidney endpoint [hazard ratio (HR) 1.53 (95% CI 1.05-2.23), P = 0.03]. However, this association lost significance after adjustment for age and sex and remained unassociated after adjustment for additional confounders [final model: HR 0.80 (95% CI 0.50-1.29), P = 0.4]. CONCLUSIONS: These data do not show that thiazide diuretics have a detrimental effect on the rate of disease progression in ADPKD and suggest that these drugs can be prescribed as second-line antihypertensives.
引用
- Kramers BJ, Koorevaar IW, De Boer R, et al. Thiazide diuretics and the rate of disease progression in autosomal dominant polycystic kidney disease: an observational study. Nephrol Dial Transplant. 2021. PMID: 33150452. doi:10.1093/ndt/gfaa150
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。